Shares of Clarient Inc., a San Juan Capistrano-based company that provides cancer testing and drug discovery services, saw its shares surge Friday after it signed a deal with Pfizer Inc.
The pact calls for Clarient’s BioPharma services business unit to provide biopharmaceutical research services for the New York-based drug maker, including immunohistochemistry and analysis of rare cells in systemic circulation.
Clarient’s shares shot up some 20% on the news. The company is small, with a market value of about $75 million with shares trading in the $1 range.
Previously known as ChromaVision Medical Systems Inc., Clarient changed its name in March.
